Profile data is unavailable for this security.
About the company
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
- Revenue in INR (TTM)104.74bn
- Net income in INR15.03bn
- Incorporated1972
- Employees13.57k
- LocationTorrent Pharmaceuticals LtdTorrent House, Off. Ashram RoadAHMEDABAD 380009IndiaIND
- Phone+91 7 926599000
- Fax+91 7 926582100
- Websitehttps://www.torrentpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories Ltd | 126.34bn | 15.73bn | 613.24bn | 16.87k | 38.98 | -- | 32.81 | 4.85 | 131.58 | 131.58 | 1,056.65 | -- | -- | -- | -- | 7,488,804.00 | -- | 11.44 | -- | 17.01 | 59.75 | 58.84 | 12.46 | 13.31 | -- | 5.83 | -- | 30.96 | 9.08 | 12.52 | -40.19 | 9.30 | -19.38 | 13.97 |
| Aurobindo Pharma Ltd | 278.95bn | 27.70bn | 660.68bn | 15.69k | 23.87 | -- | 15.43 | 2.37 | 47.25 | 47.25 | 475.59 | -- | -- | -- | -- | 17,778,640.00 | -- | 9.84 | -- | 14.92 | 55.29 | 53.05 | 9.92 | 13.06 | -- | 23.89 | -- | 8.33 | 5.97 | 8.54 | -27.21 | -4.47 | 12.20 | 3.71 |
| Lupin Ltd | 200.11bn | 19.14bn | 733.10bn | 18.97k | 38.40 | 5.13 | 23.40 | 3.66 | 41.89 | 41.89 | 437.85 | 313.60 | 0.8524 | 1.41 | 4.36 | -- | 8.24 | 1.43 | 13.34 | 2.22 | 66.80 | 59.70 | 9.67 | 2.04 | 0.9991 | 8.64 | 0.1689 | 79.28 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Torrent Pharmaceuticals Ltd | 104.74bn | 15.03bn | 879.92bn | 13.57k | 58.50 | -- | 38.27 | 8.40 | 44.44 | 44.44 | 309.68 | -- | -- | -- | -- | 7,716,901.00 | -- | 6.70 | -- | 10.48 | 74.12 | 70.84 | 14.35 | 11.22 | -- | 6.32 | -- | 63.62 | 13.07 | 10.09 | 60.22 | 12.92 | -6.22 | 25.74 |
| Mankind Pharma Ltd | 99.46bn | 17.27bn | 896.02bn | 18.47k | 51.92 | -- | 41.93 | 9.01 | 43.08 | 43.08 | 248.12 | -- | -- | -- | -- | 5,385,717.00 | -- | -- | -- | -- | 68.37 | -- | 17.68 | -- | -- | 144.35 | -- | -- | 12.44 | -- | -10.58 | -- | -- | -- |
| Dr Reddy's Laboratories Ltd | 280.11bn | 55.78bn | 986.02bn | 24.83k | 17.70 | 3.49 | 13.99 | 3.52 | 334.61 | 334.61 | 1,680.33 | 1,696.70 | 0.7874 | 1.46 | 3.67 | -- | 15.68 | 11.37 | 21.05 | 16.02 | 70.69 | 66.52 | 19.91 | 14.63 | 1.92 | 41.27 | 0.0662 | 16.40 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Zydus Lifesciences Ltd | 186.81bn | 29.56bn | 988.27bn | 23.03k | 33.63 | -- | 26.77 | 5.29 | 29.21 | 29.38 | 184.58 | -- | -- | -- | -- | 8,113,133.00 | -- | 7.92 | -- | 12.61 | 66.21 | 60.14 | 15.81 | 12.89 | -- | -- | -- | 20.55 | 14.08 | 7.59 | -12.34 | 1.83 | -0.3532 | 11.38 |
| Divi's Laboratories Ltd | 74.93bn | 13.83bn | 1.01tn | 16.95k | 72.80 | -- | 57.45 | 13.44 | 52.11 | 52.11 | 282.31 | -- | -- | -- | -- | 4,420,514.00 | -- | 18.50 | -- | 20.48 | 59.23 | 57.21 | 18.46 | 27.90 | -- | -- | -- | 31.31 | -13.31 | 14.70 | -38.41 | 15.76 | 11.55 | 24.57 |
| Cipla Ltd | 253.50bn | 37.08bn | 1.08tn | 26.62k | 29.17 | -- | 22.29 | 4.27 | 45.92 | 45.92 | 313.91 | -- | -- | -- | -- | 9,524,760.00 | -- | 8.61 | -- | 10.60 | 65.16 | 57.97 | 14.77 | 11.17 | -- | 47.26 | -- | 19.05 | 4.55 | 8.38 | 11.33 | 14.71 | 7.70 | 23.16 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 3.82m | 1.13% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 3.40m | 1.00% |
| Kotak Mahindra Asset Management Co. Ltd.as of 30 Apr 2024 | 3.34m | 0.99% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.63m | 0.78% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 30 Apr 2024 | 2.26m | 0.67% |
| ICICI Prudential Life Insurance Co. Ltd. (Invt Port)as of 30 Apr 2024 | 2.15m | 0.64% |
| Goldman Sachs Asset Management LPas of 09 May 2024 | 1.71m | 0.51% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 1.71m | 0.50% |
| Templeton Asset Management Ltd.as of 31 Dec 2023 | 1.64m | 0.49% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Apr 2024 | 1.53m | 0.45% |
